Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Unlocking Approval: Sofie Berg from AbbVie in a Riveting Conversation with PharmaShots 
Shots:  AbbVie adds an eighth indication to Rinvoq’s label with the European Commission’s approval for treating adult patients with giant cell arteritis (GCA)  Sofie Berg, Therapeutic Area Head of International Immunology at AbbVie, in a conversation with PharmaShots, shares insights from the SELECT-GCA trial evaluating Rinvoq in GCA, highlighting both primary and secondary endpoints  Rinvoq…
July 9, 2025
Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 
Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…
July 2, 2025
Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 
Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…
June 30, 2025
Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
Shots:  At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria  The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab   PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
June 23, 2025
Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots 
Shots:  In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL  Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression  PharmaShots welcomes Dr. Ira Zackon,…
June 18, 2025
Mitigating Cardiovascular Therapy Gaps: Saif Rathore and Andrew Epstein in a Riveting Conversation with PharmaShots
Mitigating Cardiovascular Therapy Gaps: Saif Rathore and Andrew Epstein in a Riveting Conversation with PharmaShots
Shots:  Did you know that coronary stent usage can decline by 20 percent if GLP-1 therapy is used as widely as statin therapy?  PharmaShots welcomes Saif Rathore, Founder of Sandbar Life Sciences and Entrepreneur-in-Residence at Yale Ventures, and Andrew Epstein, Principal at Medicus Economics, for an illuminating dialogue exchange  Saif and Andrew highlight the untapped…
June 4, 2025
Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
Shots:  Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis  The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025
Load more